Shares of Dechra Pharmaceuticals plc (LON:DPH) have been assigned a consensus recommendation of “Buy” from the eight research firms that are currently covering the company. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is GBX 1,296.43 ($16.04).

Several research analysts have weighed in on DPH shares. Numis Securities Ltd reaffirmed an “add” rating and set a GBX 1,285 ($15.90) target price on shares of Dechra Pharmaceuticals plc in a research note on Friday, June 24th. Jefferies Group increased their target price on shares of Dechra Pharmaceuticals plc from GBX 1,099 ($13.60) to GBX 1,189 ($14.72) and gave the stock a “hold” rating in a research note on Thursday, June 30th. FinnCap reaffirmed an “under review” rating on shares of Dechra Pharmaceuticals plc in a research note on Tuesday, August 30th. Panmure Gordon reaffirmed a “buy” rating and set a GBX 1,140 ($14.11) target price on shares of Dechra Pharmaceuticals plc in a research note on Monday, September 5th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a GBX 1,250 ($15.47) target price on shares of Dechra Pharmaceuticals plc in a research note on Monday, September 5th.

Shares of Dechra Pharmaceuticals plc (LON:DPH) traded up 0.73% on Friday, hitting GBX 1380.00. 93,355 shares of the stock were exchanged. The company’s 50 day moving average is GBX 1,362.76 and its 200-day moving average is GBX 1,232.72. Dechra Pharmaceuticals plc has a 52-week low of GBX 811.00 and a 52-week high of GBX 1,462.00. The stock’s market cap is GBX 1.28 billion.

The firm also recently declared a dividend, which will be paid on Friday, November 18th. Stockholders of record on Thursday, October 27th will be given a dividend of GBX 12.91 ($0.16) per share. This represents a dividend yield of 0.92%. The ex-dividend date of this dividend is Thursday, October 27th. This is a boost from Dechra Pharmaceuticals plc’s previous dividend of $5.55.

Dechra Pharmaceuticals plc Company Profile

Dechra Pharmaceuticals PLC is a veterinary pharmaceuticals company. The Company is engaged in the development, manufacture and marketing of products for veterinarians across the world. The Company’s segments include European Pharmaceuticals, consists of Dechra Veterinary Products EU and Dechra Pharmaceuticals Manufacturing; North American (NA) Pharmaceuticals, consists of Dechra Veterinary Products US and Dechra Veterinary Products Canada, and Pharmaceuticals Research and Development.

Receive News & Stock Ratings for Dechra Pharmaceuticals plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals plc and related stocks with our FREE daily email newsletter.